Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Career
    • Practice Management
      • Reimbursement & Coding
      • Legal
      • Operations
    • Awards
    • Certification
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Compensation Reports
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • By the Numbers
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • mTBI Resource Center
    • ACEP.org
    • ACEP Knowledge Quiz
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • Issue Archives
  • Archives
    • Brief19
    • Coding Wizard
    • Images in EM
    • Care Team
    • Quality & Safety
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Oral Vancomycin Curbs C. difficile Recurrence in Some Patients

By Scott Baltic | on November 22, 2016 | 0 Comment
ED Critical Care Uncategorized
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

They added, however, that in the context of secondary prophylaxis, where C. difficile load is minimal, a lower vancomycin dosage, such as 125 mg once or twice daily, might remain effective, while minimizing disruption of normal flora, but that dosage would require further study. (The most common vancomycin dosage in this study was 125 mg four times a day.)

You Might Also Like
  • Early Fecal Transplant Improves Survival after Severe C. Diff Infection
  • Experimental Antibody Reduces Risk of C. difficile Recurrence
  • How to Minimize Diarrhea Risk for Patients Taking IV Antibiotics

Pages: 1 2 | Single Page

Topics: AntibioticsClostridium difficileCritical CareinfectionInfectious DiseasePatient CareResearch

Related

  • Peritonsillar Abscess Management Tip: Put Your Scalpel Down

    January 10, 2026 - 0 Comment
  • Opinion: Emergency Physicians Witness the Universal Truth of Humanity

    January 9, 2026 - 3 Comments
  • Case Report: Five Days of Fever

    December 16, 2025 - 3 Comments

Current Issue

ACEP Now: January 2026

Download PDF

Read More

No Responses to “Oral Vancomycin Curbs C. difficile Recurrence in Some Patients”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*


Current Issue

ACEP Now: January 2026

Download PDF

Read More

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603